EUCTR2008-005037-30-ES
Active, not recruiting
Phase 1
FASE 2 DEL ESTUDIO PILOTO, QUE EVALUA LA INMUNOGENICIDAD Y LA SEGURIDAD DE IC43 EN PACIENTES EN LA UNIDAD DE CUIDADOS INTENSIVOS Original title: A PHASE 2 PILOT STUDY ASSESSING IMMUNOGENICITY AND SAFETY OF IC43 IN INTENSIVE CARE PATIENTS - IC43-201
ConditionsInfecciones nosocomiales causadas por pseudomonas aeruginosa en pacientes con ventilacion mecanica admitidos en unidades de cuidados intensivos.(Nosocomial pseudomonas aureginosa infections in mechanically ventilated ICU patients)MedDRA version: 9.1Level: PTClassification code 10061471Term: Pseudomonas infection
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Infecciones nosocomiales causadas por pseudomonas aeruginosa en pacientes con ventilacion mecanica admitidos en unidades de cuidados intensivos.(Nosocomial pseudomonas aureginosa infections in mechanically ventilated ICU patients)
- Sponsor
- Intercell AG
- Enrollment
- 450
- Status
- Active, not recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Male and female patients aged between 18 and 80 years.
- •Patients admitted to an ICU with a need for mechanical ventilation for more than 48 hours at visit 0
- •At high risk for acquiring infection against P. aeruginosa (i.e. previous treatment against P. aeruginosa, diminished lung function, high probability for requiring ventilation for more than 48 hours) at visit 0\.
- •Patients who, as determined by the investigator, have a high probability of survival for at least 48 hours.
- •In females, either childbearing potential terminated by surgery or 1 year post menopausal, or a negative pregnancy test and the willingness of practicing a reliable methods of contraception, as specified in protocol Section 6\.4
- •Written informed consent (e.g. by the patient or legal representative) or waiver according to the national regulations
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range
Exclusion Criteria
- •Known use of any other investigational or non\-registered drug (except the study vaccine) within 30 days prior to IC43 vaccination at Visit 0
- •Low severity of illness defined by an acute physiology score \< 8 at visit 0
- •Patients \< 6 months post organ transplantation
- •Severe thrombocytopenia or other coagulopathy which in the opinion of the investigator makes the patient unsuitable for intramuscular injection
- •Pregnancy (positive pregnancy test at study entry), lactation
- •Persons who have been committed involuntarily to an institution, e.g. mental health facility or prison, will not participate in the study
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Etude de phase II évaluant l'immunogénicité et la tolérance d'un vaccin inactivé non adjuvanté contre la grippe A/H1N1v chez la femme enceinte - PREFLUVACGrippe A H1N1MedDRA version: 12.0Level: LLTClassification code 10016797Term: Flu-like symptomsEUCTR2009-016660-36-FRInserm
Active, not recruiting
Not Applicable
Etude de phase II évaluant l'immunogénicité et la tolérance d'un vaccin inactivé non adjuvanté contre la grippe A (H1N1) après transplantation rénale - TRANSFLUVACEUCTR2009-016659-23-FRInserm
Active, not recruiting
Not Applicable
ENSAYO CLÍNICO PARA EVALUAR LA EFICACIA DE LA COMBINACIÓN DE INTERFERÓN PEGILADO MÁS RIBAVIRINA MÁS NITAZOXANIDA EN INDIVIDUOS CON HEPATITIS CRÓNICA DEBIDA A GENOTIPO 4 DEL VHC Y COINFECTADOS POR VIHInfección por el VIH-1 y el genotipo 4 del virus de la hepatitis CMedDRA version: 14.0Level: LLTClassification code 10065949Term: HCV coinfectionSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 14.0Level: LLTClassification code 10008922Term: Chronic infection with HIVSystem Organ Class: 10021881 - Infections and infestationsTherapeutic area: Diseases [C] - Virus Diseases [C02]EUCTR2010-024336-42-ESJUAN MACIAS SANCHEZ
Active, not recruiting
Phase 1
Etude de phase II, multicentrique, évaluant l’efficacité et la tolérance d’une association Réirradiation-Erbitux chez des patients précédemment irradiés et présentant une récidive locale inopérable d’un carcinome épidermoïde de la tête et du cou - Réirradiation et Erbitux dans les cancers des VADSEUCTR2009-015457-21-FRGORTEC
Active, not recruiting
Phase 1
Etude de phase II randomisée évaluant l'immunogénicité et la tolérance du vaccin antigrippal A(H1N1)v adjuvanté comparativement au vaccin antigrippal A(H1N1)v non adjuvanté chez des patients infectés par le VIH (ANRS 151 HIFLUVAC) - HIFLUVACinfection VIH et vaccination anti-grippe A (H1N1)MedDRA version: 12.0Level: LLTClassification code 10016794Term: Flu vaccinationMedDRA version: 12.0Level: LLTClassification code 10020161Term: HIV infectionEUCTR2009-016226-13-FRAgence nationale de recherches sur le sida et les hépatites virales